+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Systemic Lupus Erythematosus Market by Drug Type, Mode of Delivery - Global Forecast 2025-2030- Product Image
Systemic Lupus Erythematosus Market by Drug Type, Mode of Delivery - Global Forecast 2025-2030- Product Image
Sale

Systemic Lupus Erythematosus Market by Drug Type, Mode of Delivery - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5666463
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Systemic Lupus Erythematosus Market grew from USD 2.04 billion in 2023 to USD 2.24 billion in 2024. It is expected to continue growing at a CAGR of 10.54%, reaching USD 4.12 billion by 2030.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease characterized by the body's immune system attacking its own tissues, leading to inflammation and potential damage to various organs. The necessity of effective diagnosis and treatment solutions for SLE arises from its chronic nature and its impact on patient quality of life. Applications span pharmaceuticals for symptomatic relief to advanced biologics for targeted therapy, with end-use primarily in healthcare and diagnostic centers. Market growth is significantly influenced by the increasing prevalence of autoimmune diseases, rising awareness, and advancements in personalized medicine. Key potentials lie in the increased R&D for novel biologics, which offer targeted approaches with potentially reduced side effects. Companies can leverage the growing biotechnology sector to develop innovative treatments, with biosimilars offering a cost-effective alternative. However, challenges such as high treatment costs, adverse effects of long-term use of immunosuppressants, and a lack of awareness in developing regions pose limitations. Additionally, the complexity of the disease, which varies significantly between patients, complicates research and development efforts. The market can benefit from greater emphasis on personalized and precision medicine, ensuring safer and more effective patient outcomes. Investment in advanced diagnostic tools, such as biomarker discovery and genotyping, can improve early detection and treatment personalization. Collaborations with academic institutions and leveraging artificial intelligence for big data analytics present promising areas for innovation and research, contributing to a deeper understanding of the disease and the creation of cutting-edge therapies. Despite the promising outlook, the nature of the SLE market remains competitive and dynamic, driven by rapid technological advancements and evolving regulatory landscapes. Companies must stay agile, investing in focused research and strategic partnerships to navigate these challenges and capitalize on emerging opportunities for sustainable growth.

Understanding Market Dynamics in the Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing prevalence of systemic lupus erythematosus worldwide
    • Rising awareness of inflammatory autoimmune diseases and treatment
    • Improvement in healthcare infrastructure and lupus treatment clinics
  • Market Restraints
    • High cost of treatment and lack of infrastructure in low-income countries
  • Market Opportunities
    • Significant funding and investment for lupus research activities
    • Advancement in treatment technologie and launch of new products
  • Market Challenges
    • Complications in treatment and other difficulties in managing SLE

Exploring Porter’s Five Forces for the Systemic Lupus Erythematosus Market

Porter’s Five Forces framework further strengthens the insights of the Systemic Lupus Erythematosus Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Systemic Lupus Erythematosus Market

External macro-environmental factors deeply influence the performance of the Systemic Lupus Erythematosus Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Systemic Lupus Erythematosus Market

The Systemic Lupus Erythematosus Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Systemic Lupus Erythematosus Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Amgen Inc., AstraZeneca PLC, Aurinia Pharmaceuticals Inc., bioMérieux SA, Boston Pharmaceuticals Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, Hoffmann-LA-Roche Ltd., ImmuPharma PLC, Mylan N.V., Novartis AG, Pfizer, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Systemic Lupus Erythematosus Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Type
    • Antimalarial Drugs
      • Chloroquine
      • Hydrochloroquine
    • B-Cell Modulators
    • Biologics
      • Approved Biologics for Treating SLE
        • B-Cell Targeted Therapy
        • Blys-Blockers (Belimumab)
      • Biologics Used Off-Label
    • Cytotoxic & Immunosuppressive Drugs
      • Cyclophosphamide
      • Cyclosporine
      • Methotrexate
      • Mycophenolate Mofetil or Tacrolimus
    • Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
    • Non-Steroidal Anti-Inflammatory Drugs
    • Pro-Inflammatory & Cytokine Inhibitors
  • Mode of Delivery
    • Intravenous
    • Oral
    • Subcutaneous
    • Topical
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of systemic lupus erythematosus worldwide
5.1.1.2. Rising awareness of inflammatory autoimmune diseases and treatment
5.1.1.3. Improvement in healthcare infrastructure and lupus treatment clinics
5.1.2. Restraints
5.1.2.1. High cost of treatment and lack of infrastructure in low-income countries
5.1.3. Opportunities
5.1.3.1. Significant funding and investment for lupus research activities
5.1.3.2. Advancement in treatment technologie and launch of new products
5.1.4. Challenges
5.1.4.1. Complications in treatment and other difficulties in managing SLE
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Systemic Lupus Erythematosus Market, by Drug Type
6.1. Introduction
6.2. Antimalarial Drugs
6.2.1. Chloroquine
6.2.2. Hydrochloroquine
6.3. B-Cell Modulators
6.4. Biologics
6.4.1. Approved Biologics for Treating SLE
6.4.1.1. B-Cell Targeted Therapy
6.4.1.2. Blys-Blockers (Belimumab)
6.4.2. Biologics Used Off-Label
6.5. Cytotoxic & Immunosuppressive Drugs
6.5.1. Cyclophosphamide
6.5.2. Cyclosporine
6.5.3. Methotrexate
6.5.4. Mycophenolate Mofetil or Tacrolimus
6.6. Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
6.7. Non-Steroidal Anti-Inflammatory Drugs
6.8. Pro-Inflammatory & Cytokine Inhibitors
7. Systemic Lupus Erythematosus Market, by Mode of Delivery
7.1. Introduction
7.2. Intravenous
7.3. Oral
7.4. Subcutaneous
7.5. Topical
8. Americas Systemic Lupus Erythematosus Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Systemic Lupus Erythematosus Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Systemic Lupus Erythematosus Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET RESEARCH PROCESS
FIGURE 2. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2030 (%)
FIGURE 9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET DYNAMICS
TABLE 7. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY HYDROCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BLYS-BLOCKERS (BELIMUMAB), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS USED OFF-LABEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MYCOPHENOLATE MOFETIL OR TACROLIMUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY IMMUNOSUPPRESSIVE & CYTOTOXIC DRUGS & T-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY PRO-INFLAMMATORY & CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 53. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 55. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 56. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 57. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 58. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 59. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 85. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 87. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 88. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 89. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 90. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 91. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 93. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 94. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 95. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 96. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 103. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 105. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 107. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 108. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 139. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 141. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 143. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 144. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 160. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 162. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 164. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 166. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 168. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 170. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 171. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 172. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 176. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 182. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 184. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 186. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 194. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 196. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 197. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 198. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 199. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 212. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 213. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 214. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 218. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 219. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 220. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 221. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 222. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 223. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 224. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 226. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 227. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 228. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 229. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 248. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 249. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 250. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 252. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 266. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 267. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 268. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 270. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 271. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 284. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 285. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Systemic Lupus Erythematosus Market, which are profiled in this report, include:
  • Abbvie, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurinia Pharmaceuticals Inc.
  • bioMérieux SA
  • Boston Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hoffmann-LA-Roche Ltd.
  • ImmuPharma PLC
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Xencor, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages184
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.24 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.12 Billion
Compound Annual Growth Rate10.5%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Systemic Lupus Erythematosus (SLE) Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery (Intravenous, Subcutaneous, Oral), and Region 2024-2032 - Product Image

Systemic Lupus Erythematosus (SLE) Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery (Intravenous, Subcutaneous, Oral), and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
Systemic Lupus Erythematosus Market Insight, Epidemiology And Market Forecast - 2034 - Product Image

Systemic Lupus Erythematosus Market Insight, Epidemiology And Market Forecast - 2034

  • Report
  • 180 Pages
  • Global
From
Systemic Lupus Erythematosus Treatment Global Market Report 2024 - Product Image

Systemic Lupus Erythematosus Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Systemic Lupus Erythematosus Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Systemic Lupus Erythematosus Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Systemic Lupus Erythematosus (Sle) Drugs - Global Strategic Business Report - Product Image

Systemic Lupus Erythematosus (Sle) Drugs - Global Strategic Business Report

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.